Next steps in clinical translation First-in-human safety trials (phase I) are essential: to assess dose tolerability, pharmacokinetics, biodistribution, peptide half-life, clearance, immunogenicity
Vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), and platelet-derived growth factor (PDGF), along with their receptors, are key proangiogenic factors
Product type: Daily skin care soap for brightening and cleansing the skin
Category 1 contains nominated bulk substances under evaluation and is part of an FDA interim enforcement policy while the formal list is developed
Pyridoxine (B) in high doses is known to interact with certain drugs: it can reduce the therapeutic efficacy of levodopa by increasing peripheral conversion of levodopa to dopamine (vitamin B speeds up decarboxylation)
Of note, histological and cell biological changes in the developing brain are accompanied by functional changes